GutGutGoose

Startup

Probiotics that engraft. Most don't.

GutGutGoose predicts which probiotic strains will engraft in a specific person's gut, then verifies the prediction by re-sequencing six months later.

Industry-wide, off-the-shelf probiotic strains engraft at 1–10%. The microbiome literature has known this for more than a decade. GutGutGoose closes the loop: a customer mails a stool sample, the prediction pipeline (AGORA2 metabolic reconstructions, MICOM community simulation, Bayesian optimisation) identifies which combination of 40+ TGA-licensed strains will colonise that specific gut, the matched formulation ships, and at day 180 the customer re-sequences to verify what engrafted.

Across two independent clinical studies, prediction accuracy is ~80% (83.8% on Study A, 74.2% on Study B). In an alpha cohort of 20 customers, strain colonisation moved from 5% to 70%, a 14× lift over off-the-shelf benchmarks.

Provisional patent filed March 2026. 200 expressions of interest on the early-access waitlist. 80 customers committed $350 deposits each ($28,000 pre-revenue).

We've got a pod at S28 - swing by for free Kitkats and give us your best microbiome question!

website